Jasper Therapeutics Reports Promising Results in Briquilimab Studies for Chronic Spontaneous Urticaria and Chronic Inducible Urticaria

Jasper Therapeutics reports promising results from its BEACON Phase 1b/2a study on briquilimab for chronic spontaneous urticaria and chronic inducible urticaria, with 83% of participants experiencing complete response by the third week post-initial dose. The biotech company faces financial challenges with a negative earnings per share and high volatility. Its valuation metrics reveal a high price-to-book ratio and mixed moving average signals. Institutional ownership is strong, but insider ownership is low. The stock is classified as "Distressed."